The present disclosure relates generally to syringes and injectors. More specifically, the present disclosure relates to vial-to-syringe converters for container closure devices.
Prefilled syringes and cartridges are highly accurate parenteral devices used for the delivery of many vaccines, biologics, therapies, and the like. Parenteral products contain many advantages such as minimizing drug waste and increasing product life span. Additionally, parenteral devices are easily recognized by healthcare workers as a convenient method of drug delivery. One disadvantage to these parental devices is that they are typically introduced later in the drug development process and require long, complex procedures to satisfy various agency requirements through clinical trials. This, for examples, includes having a better understanding of all components, materials and interactions needed in the container closure system that creates the parenteral delivery. This process can delay critical drugs to clinic and to market.
Thus, there exists a need for devices that improve upon and advance the methods of safely bridging the gap between early drug development phases and later drug development phases.
In one embodiment, a system of creating a vial with a luer-lock functional area for use as a syringe (vial-syringe adaptor) and used as a convenient method of drug delivery. In some embodiments, vial-to-syringe converter includes a plunger rod, an adapter including a body having a piercing spike, a receiver and a lumen extending between the spike and the receiver, the adapter further including at least one laterally-extending flange, and a needle in communication with the receiver and configured to deliver the medicament to a patient's body.
In some embodiments, a system of delivering a medicament includes a vial-to-syringe converter including a plunger rod, an adapter including a body having a piercing spike, a receiver and a lumen extending between the spike and the receiver, the adapter further including at least one laterally-extending flange, and a needle in communication with the receiver and configured to deliver the medicament to a patient's body, and a vial comprising a borosilicate glass body defining a chamber, a stopper disposed inside the glass body and translatable relative thereto, and a septum disposed opposite the stopper.
In some embodiments, a system of delivering a medicament includes a vial-to-syringe converter including a plunger rod, an adapter including a body having a piercing spike, a receiver and a lumen extending between the spike and the receiver, the adapter further including at least one laterally-extending flange, and a needle in communication with the receiver and configured to deliver the medicament to a patient's body, and a vial comprising a borosilicate glass body, a first stopper disposed inside the glass body and translatable relative thereto, a second stopper disposed inside the glass body and translatable relative thereto, the second stopper being spaced from the first stopper and defining a first chamber on one side and a second chamber on an opposite side, a septum disposed opposite the stopper, and a bypass disposed adjacent the second stopper.
In some embodiments, a system of delivering a medicament includes a vial-to-syringe converter for use in single dose vials or multidose vials. In some embodiments, a system of delivering a medicament includes a vial-to-syringe converted for use in liquid, liquid-liquid, and liquid-dry products.
Various embodiments of the presently disclosed syringe assemblies and converters are disclosed herein with reference to the drawings, wherein:
Various embodiments will now be described with reference to the appended drawings. It is to be appreciated that these drawings depict only some embodiments of the disclosure and are therefore not to be considered limiting of its scope.
Despite the various improvements that have been made to container closure devices, injectors and syringes, such as pre-filled syringes, conventional methods suffer from some shortcomings as discussed above.
Therefore, there is a need for further improvements to the devices and methods used to deliver medication. Among other advantages, the present disclosure may address one or more of these needs.
As used herein, the term “proximal,” when used in connection with a component of a syringe or injector, refers to the end of the component closest to the user's hands when holding the device, whereas the term “distal,” when used in connection with a component of a syringe or injector, refers to the end of the component closest to the needle insertion site during use.
Likewise, the terms “trailing” and “leading” are to be taken as relative to the operator's fingers (e.g., physician) of the syringe or injector. “Trailing” is to be understood as relatively close to the operator's fingers, and “leading” is to be understood as relatively farther away from the operator's fingers.
Reference is now made to
A cylindrical barrel 120 extends between proximal end 122 and distal end 124 and comprises a body 125 defining a lumen 126 for accepting a portion of plunger rod 110. Body 125 further comprises a barrel flange 127 adjacent proximal end 122 and defines a reservoir “R” that holds a medicament, drug, saline, or other substance for injecting into a patient's body. An internally threaded stopper 130 is disposed inside lumen 126 of body 125. In one embodiment, stopper 130 is made of an elastomeric material such as natural rubber, synthetic rubber, thermoplastic elastomers, or combinations thereof, and comprises an opening to receive and mate with coupler 119 of plunger rod 110 by advancing the plunger rod inside the barrel lumen 126 and rotating at least one of coupler 119 and stopper 130 relative to the other.
In this example, pre-filled syringe 100 includes a spring 132 operatively coupled to needle 134 to provide an additional safety mechanism. A cap 135 is also disposed over needle 134. Once cap 135 is removed, the user may pierce the patient's skin with the needle, then push on plunger flange 117 to drive the plunger to deliver a medicament through needle 134 into the patient's body. Spring 130 is configured so that, upon actuation and full delivery of the medicament, needle 134 will safely retract within barrel 120 and be locked inside to reduce the risk of needlestick injuries.
In some embodiments, a vial and a converter combination may be used instead of a traditional pre-filled syringe that requires regulatory approval. Turning to
Body 202 itself defines a main chamber 203 for receiving a substance “S” or medicament (e.g., vaccine, biologic, therapeutic, drug product for use in early drug development phases, etc.), and a latex septum 204 having a circumferential aluminum crimp 205 disposed on an opposite end. Vials 200 may be protected inside shell 220 that includes a body 222 and a protective cap 224. Shell 220 may be useful for ease of labeling when the drug products requires conditioning or storage in conditions outside of a standard range. In one embodiment, the shell comprises any medical grade plastic and/or polymer that is presently on the market. In a further embodiment, the shell comprises polypropylene.
As shown in
Plunger rod 310 may generally include an actuating base 311, an elongated cruciform shaft 312 and a vial contacting member 313. As shown, actuating base 311 may be substantially circular and enlarged relative to the shaft and the contacting member so that a user can press on it with their thumb or other digit. In some examples, plunger 310 is formed of a unitary body made of any medical grade plastic and/or polymer that is presently on the market. In one embodiment, the plunger comprises polypropylene.
Adapter 320 may also be formed of any medical grade plastic and/or polymer that is presently on the market. In one embodiment, adapter comprises polypropylene. Adapter 320 may include a piercing device/apparatus 321 (a feature that creates an access from vial i.e. a fluid path), a body 324 defining a pair of finger flanges 322, and a needle receiver 323 disposed opposite the spike 321. The adapter 320 may define an axial lumen 325 that extends from the piercing spike 321 through the body and the receiver 323. Optionally, a plurality of wings 326 may be circumferentially disposed about the piercing spike 321 and configured to accept and/or stabilize a portion of a vial. Needle receiver 323 may be sized to accept a hub 331 of a needle 330 so that the hub 331 can be pressed or twisted into the receiver 323 to mate the two components together and establish a passage for fluid communication from spike 321 of adapter 320 to the distal tip 332 of needle 330. In at least some examples, needle 330 may be a conventional luer-lock needle, and the receiver 323 includes an internal threading that complements the luer-lock threading of the needle hub.
Turning to
To use the system, a clinician, patient, or user may assemble the components as described above, or the components may be pre-assembled by a manufacturer or care provider. The distal end of needle 330 may be pierced into a body part (e.g., the patient's arm). To deliver the drug product into the patient, the user may simply grasp the finger flanges 322 of adapter 320 with, for example, their index and middle fingers, and press against the plunger rod 310 with their thumb so that the plunger rod pushes the stopper 206 of the vial 200 through the body 202, and the contents of the main chamber 203 flow through passageway 350 (i.e., through the spike, the adapter body, the hub of the needle and the distal end of the needle) into the patient's body.
Thus, a single vial 200 may be used in different phases of development while minimizing regulatory and safety risks. In this manner, the converter provides a simple, easy-to-use method to accurately deliver a single dose from a custom vial 200 and to transform the vial into an easy-to-recognize parental syringe assembly. Among the advantages of this configuration are the benefits of providing a way for patients to self-administer at home, reducing environmental waste, reducing development time, decreasing time to market, and improving access to underserved markets. Additionally, the present embodiments reduce the need to overfill a drug product to account for waste during withdrawal, which is beneficial for programs or stages where drug availability is limited.
In another embodiment, a dual-chamber vial 500 may include a glass body 502, a latex septum 504 and a crimp 505 similar to that of
In some examples, the two chambers contain a two-drug product combination so that two different substances may be stored separately and introduced together. For example, a first liquid may be disposed in the first chamber, and a second liquid may be disposed in the second chamber. Alternatively, a liquid may be disposed in the first chamber, and a lyophilized product may be disposed in the second chamber. In at least some examples, the first chamber may contain a first pharmaceutical composition or drug substance, and the second chamber may contain a second pharmaceutical composition or drug substance. In at least some examples, the first chamber may contain any of any injectable product (lyophilized product, saline, water, drug product, medicine), and the second chamber may contain any of an injectable product that can be used in combination of chamber 1 for investigative, therapeutic, or medicine use. In one embodiment, the first chamber may contain any of one injectable product, and the second chamber may contain a different injectable product. In a further embodiment, the first and second chamber comprise injectable medical products for use in a combination.
In another embodiment, the first and second chamber comprise the same injectable medical product for use as a single administration to achieve a desired dose.
A converter system 300 may be coupled to a vial 500 to turn it into a functional syringe assembly 600 in a manner similar to that of
It is to be understood that the embodiments described herein are merely illustrative of the principles and applications of the present disclosure. For example, the number, positioning and arrangement of bypass may be varied. Additionally, more than two compartments arranged in parallel may be formed. Moreover, certain components are optional, and the disclosure contemplates various configurations and combinations of the elements disclosed herein. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present disclosure as defined by the appended claims.
It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/048565 | 11/1/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63275106 | Nov 2021 | US |